POM-V Prescription Required

Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs

Active ingredient: Flunixin

Form

Injection

Species

Cattle Horses Pigs

Manufacturer

Norbrook Laboratories Limited

VMD MA No.

02000/4170

What it's used for

Alleviation of acute inflammation and pain associated with musculoskeletal disorders. Reduction of post-operative pain associated with dehorning in calves...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Flunixin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Reduction of post-operative pain associated with dehorning in calves of less than 9
weeks.
AN: 00490/2025 and 00491/2025
Horses
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Alleviation of visceral pain associated with colic.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical
conditions or diseases that result in impaired blood circulation in the gastrointestinal tract.
Reduction of pyrexia.
Pigs
Adjunctive therapy in the treatment of swine respiratory disease.
Adjunctive treatment of postpartum dysgalactia (Mastitis-Metritis-Agalactia) syndrome in
sows.
Alleviation of acute inflammation and pain associated with musculoskeletal disorders.
Reduction of post-operative pain following castration and tail docking in sucking piglets.

Intramuscular use in pigs.
Intravenous use in horses.
AN: 00490/2025 and 00491/2025
Cattle
Adjunctive therapy in the treatment of bovine respiratory diseases, endotoxemia and
acute mastitis and alleviation of acute inflammation and pain associated with
musculoskeletal disorders
2.2 mg flunixin/kg bodyweight (2 ml per 45 kg) once daily via intravenous route. Repeat
as necessary at 24-hour intervals for up to 3 consecutive days.
Reduction of post-operative pain associated with dehorning in calves of less than 9
weeks
A single intravenous administration of 2.2 mg of flunixin per kg bodyweight (2 mL per 45
kg), 15-20 minutes before the procedure.
Horses
Alleviation of acute inflammation and pain associated with musculoskeletal disorders and
reduction of pyrexia
1.1 mg flunixin/kg bodyweight (1 ml per 45 kg) once daily for up to 5 days according to
clinical response.
Alleviation of visceral pain associated with colic
1.1 mg flunixin/kg bodyweight (1 ml per 45 kg). Repeat once or twice if colic recurs.
Adjunctive therapy of endotoxemia due to or as a result of post-surgical or medical
conditions or diseases that result in impaired blood circulation in the gastrointestinal tract
0.25 mg flunixin/kg bodyweight every 6-8 hours or 1.1 mg flunixin/kg bodyweight once
daily for up to 5 consecutive days.
Pigs
Adjunctive therapy in the treatment of swine respiratory disease, adjunctive treatment of
postpartum dysgalactia (Mastitis-Metritis-Agalactia) syndrome in sows, alleviation of
acute inflammation and pain associated with musculoskeletal disorders
2.2 mg flunixin/kg bodyweight (2 ml per 45 kg) once daily for up to 3 consecutive days.
The injection volume should be limited to a maximum of 4 ml per injection site.
Reduction of post-operative pain following castration and tail docking in sucking piglets
A single administration of 2.2 mg of flunixin per kg bodyweight (0.2 mL per 4.5 kg), 15-30
minutes before the procedure.
Particular care should be taken with regard to the accuracy of dosing including the use of
an appropriate dosing device and careful estimation of body weight.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
The stopper should not be punctured more than 50 times. A draw off needle should be
used to avoid excessive puncturing of the stopper.
AN: 00490/2025 and 00491/2025

Do not use in animals suffering from cardiac, hepatic, or renal disease or where there is
the possibility of gastro-intestinal ulceration or bleeding.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use if haematopoiesis or haemostasis is impaired.
Do not use in case of colic caused by ileus and associated with dehydration.

Cattle
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (such as injection site irritation

and
injection site swelling).
Rare
(1 to 10 animals / 10,000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Anaphylaxis (e.g. Anaphylactic shock, Hyperventilation,
Convulsion, Collapse, Death)
;
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract haemorrhage, nausea,
blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Appetite loss.
Particularly in hypovolaemic and hypotensive animals.
AN: 00490/2025 and 00491/2025
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins, responsible
for the initiation of parturition.
If the product is used in the period following parturition.
Horses
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (such as injection site irritation

and
injection site swelling).
Rare
(1 to 10 animals / 10,000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Anaphylaxis (e.g. Anaphylactic shock, Hyperventilation,
Convulsion, Collapse, Death)
;
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract haemorrhage, nausea,
blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Excitation
;
Muscle weakness
;
Appetite loss.
Particularly in hypovolaemic and hypotensive animals.
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins, responsible
for the initiation of parturition.
If the product is used in the period following parturition.
May occur through accidental intra-arterial injection.
Pigs
Uncommon
(1 to 10 animals / 1,000
animals treated):
Injection site reaction (such as injection site skin discolouration,
injection site pain, injection site irritation

and injection site
swelling)
.
Rare
(1 to 10 animals / 10,000
animals treated):
Liver disorder;
Renal disorder (Nephropathy, Papillary necrosis)
.
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Anaphylaxis (e.g. Anaphylactic shock, Hyperventilation,
Convulsion, Collapse, Death)
;
Ataxia
;
Blood and lymphatic system disorder
, Haemorrhage;
Digestive tract disorder (gastrointestinal irritation,
gastrointestinal ulceration, digestive tract haemorrhage,
vomiting, nausea, blood in faeces, diarrhoea)
;
Delay of parturition
, stillbirth
, retained placenta
;
Appetite loss.
Resolves spontaneously within 14 days.
Particularly in hypovolaemic and hypotensive animals.
AN: 00490/2025 and 00491/2025
After intravenous administration. At the onset of the first symptoms, administration
should be stopped immediately and, if necessary, anti-shock treatment should be started.
Blood count abnormalities.
By a tocolytic effect induced by inhibition of the synthesis of prostaglandins, responsible
for the initiation of parturition.
If the product is used in the period following parturition.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

None.

Special precautions for safe use in the target species:
Inject slowly as life threating symptoms of shock can occur due to the content of
propylene glycol.
NSAIDs are known to have the potential to delay parturition through a tocolytic effect by
inhibiting prostaglandins that are important in signalling the initiation of parturition. The
use of the veterinary medicinal product in the immediate post-partum period may
interfere with uterine involution and expulsion of foetal membranes resulting in retained
placentae.
The veterinary medicinal product should have a temperature close to body temperature.
Stop injection immediately after first symptoms of shock and start shock treatment if
necessary.
Use of NSAID’s in hypovolemic animals or animals with shock should be subject to a
benefit-risk evaluation performed by the responsible veterinarian due to the risk of renal
toxicity.
Use in very young (cattle, horses: less than 6 weeks old) as well as in old animals may
involve additional risks. If such treatment cannot be avoided, careful clinical observation
is indicated. The underlying cause of pain, inflammation or colic should be determined
and, when appropriate, antibiotic or re-hydration therapy should be given concurrently.
AN: 00490/2025 and 00491/2025
NSAIDs can cause phagocytosis inhibition and, therefore, in the treatment of
inflammatory states associated with bacterial infections, appropriate concurrent
antimicrobial therapy should be established.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product may cause hypersensitivity (allergy) reactions. People
with known hypersensitivity to non-steroidal anti-inflammatory drugs such as flunixin
and/or to propylene glycol should avoid contact with the veterinary medicinal product. In
case of hypersensitivity reactions seek medical advice and show the package leaflet or
the label to the physician.
This veterinary medicinal product may cause skin and eye irritation. Avoid contact with
skin or eyes. Wash hands after use. In case of accidental skin contact, wash affected
area immediately with plenty of water.
In case of accidental eye contact, rinse eyes immediately with plenty of water. If skin and
/or eye irritation persists, seek medical advice immediately and show the package leaflet
or the label to the physician.
Accidental self-injection may cause pain and inflammation. In case of accidental self-
injection, seek medical advice immediately and show the package leaflet or the label to
the physician.
Laboratory studies in rats with flunixin have shown evidence of foetotoxic effects.
Pregnant women should use the veterinary medicinal product with serious caution to
avoid accidental self-injection.
Special precautions for the protection of the environment:
Flunixin is toxic to avian scavengers. Do not administer to animals susceptible to enter
wild fauna food chain. In case of death or sacrifice of treated animals, ensure that they
are not made available to wild fauna.

Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs) concurrently or
within 24 hours of each other. Do not administer corticosteroids concurrently. Concurrent
use of other NSAIDs or corticosteroids may increase the risk of gastro-intestinal
ulceration.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly
bound drugs which can lead to toxic effects.
Flunixin may decrease the effect of some antihypertensive drugs by inhibiting
prostaglandin synthesis, such as diuretics, ACE inhibitors (angiotensin converting
enzyme inhibitors) and
Concomitant administration of potentially nephrotoxic drugs (e.g., aminoglycoside
antibiotics) should be avoided.

Do not store above 25°C.
Keep the vial in the outer carton in order to protect from light.

Cattle:
Meat and offal: 4 days.
Milk: 24 hours.
Pigs
Meat and offal: 24 days.
Horses:
Meat and offal: 5 days.
Not authorised for use in animals producing milk for human consumption.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.